[PDF][PDF] Recruit or reboot? How does anti-PD-1 therapy change tumor-infiltrating lymphocytes?
MK Callahan, JD Wolchok - Cancer Cell, 2019 - cell.com
MK Callahan, JD Wolchok
Cancer Cell, 2019•cell.comIt has been widely assumed that PD-1 blockade works by reinvigorating (" rebooting") pre-
existing exhausted tumor-infiltrating ilymphocytes (TILs). A recent study challenges this
paradigm, demonstrating that the majority of tumor-specific TILs after anti-PD-1 treatment
have TCRs not identified in the tumor pre-therapy, suggesting they are newly recruited post-
therapy.
existing exhausted tumor-infiltrating ilymphocytes (TILs). A recent study challenges this
paradigm, demonstrating that the majority of tumor-specific TILs after anti-PD-1 treatment
have TCRs not identified in the tumor pre-therapy, suggesting they are newly recruited post-
therapy.
It has been widely assumed that PD-1 blockade works by reinvigorating ("rebooting") pre-existing exhausted tumor-infiltrating ilymphocytes (TILs). A recent study challenges this paradigm, demonstrating that the majority of tumor-specific TILs after anti-PD-1 treatment have TCRs not identified in the tumor pre-therapy, suggesting they are newly recruited post-therapy.
cell.com